The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Expanded cohort and extended follow-up of neoadjuvant plus adjuvant (neo + adj) dabrafenib (D) and trametinib (T) in patients (pts) with surgically resectable stage (stg) III/IV melanoma.
 
Tarin Hennegan
No Relationships to Disclose
 
Elizabeth M. Burton
No Relationships to Disclose
 
Lauren Simpson
No Relationships to Disclose
 
Victor Gerardo Prieto
Honoraria - Castle Biosciences
Consulting or Advisory Role - Merck
 
Merrick I. Ross
Honoraria - Amgen; Merck Sharp & Dohme
Consulting or Advisory Role - Amgen; Merck Sharp & Dohme
Research Funding - Amgen; Merck Sharp & Dohme
Travel, Accommodations, Expenses - Amgen; Merck Sharp & Dohme
 
Isabella Claudia Glitza
Honoraria - Amgen
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Leal Therapeutics; Midatech Pharma; Novartis; Sintetica
Speakers' Bureau - Array BioPharma
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst)
 
Lisa G Beal
No Relationships to Disclose
 
Jeffrey E. Gershenwald
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Merck Sharp & Dohme; Novartis; Regeneron; Syndax
Patents, Royalties, Other Intellectual Property - Mercator
 
Hussein A. Tawbi
Consulting or Advisory Role - Boxer Capital; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; Jazz Pharmaceuticals; Karyopharm Therapeutics; Medicenna; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst)
 
Michael K.K. Wong
Consulting or Advisory Role - Castle Biosciences; Regeneron; Replimune
 
Zhongya Wang
No Relationships to Disclose
 
Roland L. Bassett
No Relationships to Disclose
 
Anthony Lucci
Speakers' Bureau - Exact Sciences
 
Jeffrey Edwin Lee
No Relationships to Disclose
 
Sarah B. Fisher
No Relationships to Disclose
 
Sapna Pradyuman Patel
Honoraria - Delcath Systems; Emory University
Consulting or Advisory Role - Bristol Myers Squibb; Castle Biosciences; Delcath Systems; immatics; Immunocore; Novartis; Pfizer; Replimune; TriSalus Life Sciences
Research Funding - Bristol-Myers Squibb (Inst); Foghorn Therapeutics (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - InxMed; TriSalus Life Sciences
 
Jennifer Leigh McQuade
Honoraria - Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - Bristol Myer Squibb; Roche Pharma AG
Travel, Accommodations, Expenses - Merck
 
Michael A. Davies
Consulting or Advisory Role - ABM; Apexigen; Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; NanoString Technologies; Novartis; Pfizer
Research Funding - ABM (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lead Pharma (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Pfizer (Inst); Sanofi (Inst)
 
Jennifer Ann Wargo
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Illumina; Merck
Speakers' Bureau - DAVA Oncology; Genentech; Novartis; PER/CURE Media Group; Precison Health
Research Funding - Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Novartis
 
Rodabe Navroze Amaria
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Iovance Biotherapeutics; Novartis; Obsidian Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); iovance Biotherapeutics (Inst); Merck (Inst); Novartis (Inst); Obsidian Therapeutics (Inst)